

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
27 October 2005 (27.10.2005)

PCT

(10) International Publication Number  
**WO 2005/099744 A1**

(51) International Patent Classification<sup>7</sup>: A61K 38/17, 39/395, A61P 7/02

(21) International Application Number: PCT/GB2005/001451

(22) International Filing Date: 15 April 2005 (15.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/521,385 15 April 2004 (15.04.2004) US

(71) Applicant (for all designated States except US, UZ): ATHERA BIOTECHNOLOGIES AB [SE/SE]; Fogderøreten 2B, S-17177 Stockholm (SE).

(71) Applicant (for UZ only): PILKINGTON, Stephanie [GB/GB]; Park View House, 58 View House, Nottingham NG1 5DD (GB).

(71) Applicants and

(72) Inventors (for all designated States except UZ): CEDERHOLM, Anna [SE/SE]; Jakob Westingsgatan 3, S-11220 Stockholm (SE). FROSTEGÅRD, Johan [SE/SE]; Törnrosavägen 9, S-131 47 Nacka (SE).

(74) Agents: PILKINGTON, Stephanie et al.; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

[Continued on next page]

(54) Title: ANNEXIN V FOR PREVENTING ATHEROTHROMBOIS AND PLAQUE RUPTURE



WO 2005/099744 A1

(57) Abstract: Atherosclerosis can be viewed as a response to injury and it is not atherosclerosis per se that is serious but instead factors leading to rupture of atherosclerotic plaques. In the present invention we have identified such factors. A decreased binding of Annexin V to the endothelium was seen in patients with a history of atherothrombosis. The use of native Annexin V or an N-terminal fragment as an active component or a subfraction of immunoglobulins to manufacture a pharmaceutical composition is proposed to improve said binding. The use of Annexin V, N-terminal fragments or immunoglobulins to increase the Annexin V-binding to carotid plaque represents novel mechanism for preventing atherothrombosis.



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*